Study of serplulimab plus standard therapy for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests an immunotherapy drug (serplulimab) combined with targeted therapy, chemo, and radiation as a first treatment for people with advanced colorectal cancer that has spread and cannot be surgically removed. It aims to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have colorectal cancer that has spread to other parts of the body (Stage IV) and cannot be removed with surgery.
- You have not had any prior cancer treatment like chemotherapy, targeted therapy, or immunotherapy.
- Your tumor has a specific genetic makeup (RAS and BRAF wild-type or RAS mutant) depending on where it started in the colon.
- You are in good enough health to carry out daily activities (ECOG 0 or 1) and have adequate organ function.
- You agree to use effective contraception if you could become pregnant or father a child.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of oral chemotherapy, targeted therapy, and immunotherapy, with or without radiation, for people with advanced colorectal cancer that hasn't responded to at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow the disease.
This trial tests a new immunotherapy drug called serplulimab combined with standard chemotherapy or targeted therapy for colorectal cancer that has come back within a year after surgery. The goal is to see if adding this immune-boosting drug helps control the cancer better than chemotherapy alone.
This trial tests a new approach for advanced low rectal cancer. You'll receive a combination of chemotherapy, immunotherapy, and radiation before surgery, which may help shrink the tumor and make surgery easier.
This trial tests a combination of immunotherapy (sintilimab), a targeted therapy (cetuximab), and chemotherapy as a first treatment for advanced colorectal cancer that hasn't spread or come back after earlier treatment. It's for people whose tumors have certain genetic markers (RAS/BRAF wild-type) and show signs of immune activity (PD-L1 or CD8+ TILs).
This Phase 2 trial tests serplulimab (immunotherapy) combined with FOLFIRI chemo plus bevacizumab for colon cancer that has spread to the lining of the abdomen (peritoneal metastases). It aims to shrink these tumors and improve outcomes when surgery can’t fully remove them.
This trial tests a combination of three drugs—chemotherapy plus two targeted therapies—as a first treatment for colorectal cancer that cannot be surgically removed. The goal is to shrink tumors enough to allow surgery later, potentially improving outcomes.
Hear when a new Advanced Colorectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.